ChemGenex Pharmaceuticals Limited
ChemGenex Pharmaceuticals is looking for treatments that are tailor-made for different patients. The company is researching targeted cancer therapies, finding genetic differences that affect how well patients respond to certain drugs and tailoring therapies accordingly. Its lead candidate is omacetaxine mepesuccinate (formerly called Ceflatonin); the drug is undergoing clinical testing as a treatment for chronic myeloid leukemia in patients who have a genetic mutation that makes them resistant to Novartis' Gleevec. Also in clinical development is Quinamed, a potential tumor fighter. The company has several other preclinical oncology programs as well.
Contact Details
Office Address
ChemGenex Pharmaceuticals Limited
Level 4, 199 Moorabool St.
Geelong, Victoria, Australia 3220
Phone: +61-3-5223-9900
Fax: +61-3-5229-0100
Executives
CEO and Director
Greg R. Collier
President
Dennis Brown